Vicore Pharma Holding Overview
- Year Founded
-
2005
- Status
-
Public
- Employees
-
33
- Stock Symbol
-
VICO
- Investments
-
5
- Share Price
-
$0.88
- (As of Thursday Closing)
Vicore Pharma Holding General Information
Description
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.
Contact Information
Website
www.vicorepharma.comCorporate Office
- Kornhamnstorg 53
- 111 27 Stockholm
- Sweden
Corporate Office
- Kornhamnstorg 53
- 111 27 Stockholm
- Sweden
Vicore Pharma Holding Timeline
Vicore Pharma Holding Stock Performance
As of 15-May-2025, Vicore Pharma Holding’s stock price is $0.88. Its current market cap is $206M with 235M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.88 | $0.81 | $0.62 - $2.25 | $206M | 235M | 388K | -$0.18 |
Vicore Pharma Holding Financials Summary
As of 31-Mar-2025, Vicore Pharma Holding has a trailing 12-month revenue of $563K.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 60,398 | 141,945 | 108,069 | 124,755 |
| Revenue | 563 | 10,339 | 0 | 0 |
| EBITDA | (28,998) | (17,750) | (29,959) | (28,201) |
| Net Income | (29,279) | (15,945) | (29,254) | (28,430) |
| Total Assets | 108,197 | 109,041 | 49,814 | 32,402 |
| Total Debt | 0 | 0 | 0 | 0 |
Vicore Pharma Holding Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Vicore Pharma Holding Comparisons
Industry
Financing
Details
Vicore Pharma Holding Competitors (4)
One of Vicore Pharma Holding’s 4 competitors is Gilead Sciences, a Formerly VC-backed company based in Foster City, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gilead Sciences | Formerly VC-backed | Foster City, CA | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
| Savara | Formerly VC-backed | Langhorne, PA | ||||
| Gesynta Pharma | Venture Capital-Backed | Stockholm, Sweden |
Vicore Pharma Holding Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Vicore Pharma Holding Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Vicore Pharma Holding Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Vicore Pharma Holding Investments & Acquisitions (5)
Vicore Pharma Holding’s most recent deal was a Corporate Asset Purchase with HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists) for . The deal was made on 02-Nov-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| HaLaCore (Pipeline of Novel Preclinical-Stage AT2R Agonists) | 02-Nov-2020 | Corporate Asset Purchase | Buildings and Property | ||
| INIM Pharma | 20-Aug-2018 | Merger/Acquisition | Drug Discovery | ||
| I-Tech (Biotechnology Company) | 08-Feb-2018 | Later Stage VC | Industrial Chemicals | ||
| I-Tech (Biotechnology Company) | 01-Mar-2011 | Later Stage VC | Industrial Chemicals | ||
| I-Tech (Biotechnology Company) | 01-Jan-2000 | Early Stage VC | Industrial Chemicals |
Vicore Pharma Holding ESG
Risk Overview
Risk Rating
Updated November, 10, 2023
30.44 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile
Pharmaceuticals
Industry
of 843
Rank
Percentile
Pharmaceuticals
Subindustry
of 419
Rank
Percentile
Vicore Pharma Holding Exits (3)
Vicore Pharma Holding’s most recent exit was on 08-Feb-2018 from I-Tech (Biotechnology Company). The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| I-Tech (Biotechnology Company) | 08-Feb-2018 | Completed |
|
||
| I-Tech (Biotechnology Company) | 01-Mar-2011 | Completed |
|
||
| I-Tech (Biotechnology Company) | 01-Jan-2000 | Early Stage VC | Completed |
|
Vicore Pharma Holding Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| INIM Pharma | Sweden | 2018 |
Vicore Pharma Holding FAQs
-
When was Vicore Pharma Holding founded?
Vicore Pharma Holding was founded in 2005.
-
Where is Vicore Pharma Holding headquartered?
Vicore Pharma Holding is headquartered in Stockholm, Sweden.
-
What is the size of Vicore Pharma Holding?
Vicore Pharma Holding has 33 total employees.
-
What industry is Vicore Pharma Holding in?
Vicore Pharma Holding’s primary industry is Drug Discovery.
-
Is Vicore Pharma Holding a private or public company?
Vicore Pharma Holding is a Public company.
-
What is Vicore Pharma Holding’s stock symbol?
The ticker symbol for Vicore Pharma Holding is VICO.
-
What is the current stock price of Vicore Pharma Holding?
As of 15-May-2025 the stock price of Vicore Pharma Holding is $0.88.
-
What is the current market cap of Vicore Pharma Holding?
The current market capitalization of Vicore Pharma Holding is $206M.
-
What is Vicore Pharma Holding’s current revenue?
The trailing twelve month revenue for Vicore Pharma Holding is $563K.
-
Who are Vicore Pharma Holding’s competitors?
Gilead Sciences, Amgen, Savara, and Gesynta Pharma are competitors of Vicore Pharma Holding.
-
What is Vicore Pharma Holding’s annual earnings per share (EPS)?
Vicore Pharma Holding’s EPS for 12 months was -$0.18.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
